FX11 has demonstrated the ability to inhibit LDHA and thus the effect of Warburg in pancreatic cancer cells only in the presence of mutant p53, but the high proportion of p53 mutant cells in most malignancies makes this a feasible therapeutic option (16–18). This evidence concerns the gene TP53 and familial pancreatic carcinoma.